NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week said that it is currently amending the protocol of a Phase I trial of its RNAi-based Ebola infection therapy TKM-Ebola after US regulators halted the study amid safety concerns.

Tekmira, which has seen its stock fall more than 25 percent since the US Food and Drug Administration put a hold on the clinical trial early this month, said that it expects the matter will be resolved by the end of the year. Tekmira shares closed a little over $10 on Wednesday, and remain well off a 52-week high of $31.48.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.